Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer

Table 3 Clinicopathological features of 12 skip N2 patients

Pt. no.	Age/sex	Side	Location (lobe)	Histology	Tumor size (mm)	Proportion of GGO (%)	Distance to pleura (mm)	SLX (U/mL)	ly	v	pPL	Site of skip N2
1	73/M	Rt	Upper	Sq	15	19	4	36.2	+	-	0	No. 2R, 4R LN
2	34/F	Rt	Upper	Ad	16	68	13	27.4	+	-	0	No.4R LN
3	70/F	Rt	Upper	Ad	21	47	30	21.4	+	+	0	No.2R, 4R LN
4	62/F	Rt	Upper	Ad	14	24	28	13.1	+	-	0	No. 4R LN
5	71/M	Rt	Lower	Ad	30	9	0	40.2	-	-	0	No. 7 LN
6	61/F	Rt	Lower	Ad	24	27	0	32.8	+	+	1	No. 7 LN
7	60 M	Rt	Lower	Ad	24	23	0	29.0	+	+	0	No.2R, 4R LN
8	62/F	Lt	Upper	Ad	20	72	5	23.6	+	+	1	No. 5 LN
9	81/M	Lt	Upper	Sq	27	13	0	24.5	+	-	2	No. 5 LN
10	63/M	Lt	Lower	Ad	15	38	0	28.0	+	-	0	No. 5 LN
11	60/M	Lt	Lower	Ad	23	7	14	27.0	-	+	0	No. 7 LN
12	57/F	Lt	Lower	Ad	20	3	0	33.0	+	-	0	No. 5 LN

Pt. no., patient number; M,male; F, female; Rt, right; Lt, left; Ad, adenocarcinoma; Sq, squamous cell carcinoma; GGO, ground-glass opacity; distance to pleura, measured on computed-tomography; SLX, sialyl Lewis X; ly, lymph vessel invasion factor; v, venous invasion factor; pPL, pathological pleural invasion factor; No. 2R, upper paratracheal lymph node; No. 4R LN, lower paratracheal lymph node; No. 5 LN, subaortic lymph node; No. 7 LN, subcarinal lymph node.

ISSN: 1477-7819